To the Editor: Logue et al explored the association between age, sex and BMI at the time of diagnosis of type 2 diabetes using a large cohort of patients from Scottish diabetes register [1] . They reported a significant difference in the inverse relationships between age and BMI for men and women. They also observed marked differences in the average BMI levels for men and women at younger ages, which narrowed down with advancing age.
7.9 (2) % (62.8 mmol/mol). The systolic and diastolic blood pressure were 141 (19) mmHg and 81 (10) mmHg, respectively, at the time of diagnosis of diabetes. The risk factor data were obtained within a 6 month window of the diagnosis of diabetes. The GPRD Group obtained ethical approval from a multicentre research ethics committee for all purely observational research, using anonymised records from the GPRD. The extraction of data for this study was approved by the GPRD Independent Scientific Advisory Committee.
The distributions of age, BMI and HbA 1c were significantly different between men and women. Compared with men, women were older (65 vs. 61 years) with larger proportion of obesity (53% vs. 43%) and a higher level of systolic blood pressure (143 vs. 140 mmHg), but had lower HbA 1c level (7.82% vs. 7.87%). The age-adjusted average BMI for women and men was 31.5 (95% CI 31.4, 31.6) kg/m 2 and 29.7 (95% CI 29.6, 29.9) kg/m 2 , respectively, with higher average for women by 1.8 (95% CI 1.7, 1.9)kg/m 2 (p<0.01). The observations made by Logue et al on the narrowing of BMI differences between sexes with advancing age was not immediately clear from their data. Possible significant differences in average BMI over the distribution of age needed to be explored. To evaluate the patterns of BMI differences by sex over the whole distribution of age, we conducted regression analysis with deciles of age. As evident from Fig. 1 , the average BMI level continued to be significantly higher for women until the eighth decile of age. The narrowing of BMI differences at the highest age group could be because of chance, as we had a small number of patients in the highest age groups. Although we did not have data on ethnicity, additional analyses with adjustment for blood pressure, smoking and drinking status revealed similar differences in the average BMI levels. As reported by Logue et al. our data also reveal that men, who were diagnosed with diabetes at later age (> 60 years) than women, were less likely to be obese. Our analysis provides further evidence that the findings based on the Scottish cohort data are very likely to be presenting the true population-level scenario. Funding No separate funding was obtained for this study. GT is a fully funded research higher degree student of the University of Queensland. This study is based on data from the full feature General Practice Research Database funded through the Medical Research Council's licence agreement with the UK Medicines and Healthcare Products Regulatory Agency. The interpretation and conclusions contained in this study are those of the authors alone.
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